FDA approved for treatment of Macular Edema associated with CRVO in September 2012

Lucentis

NORI participated in a total of 9 Wet AMD ranibizumab trials beginning in 2003 until 2012

FDA approved for treatment of Wet AMD June 2006

Higher success profile than Macugen®

NORI was the only clinical research site in Southwest Florida that participated in the CATT study. CATT was a National Institute of Health/National Eye Institute study comparing Lucentis to Avastin. For more information about the CATT study, please visit www.nei.nih.gov/CATT

NORI participated in 1 large DME ranibizumab trial from 2007 until 2012

FDA approved for treatment of DME August 2012

Remains the ONLY FDA approved medication for the treatment of DME

NORI participated in 3 large Macular Edema/RVO ranibizumab trials from 2007 until 2012

FDA approved for treatment of Macular Edema associated with RVO in June 2010.